Phlow receives approval to join BARDA CDMO network
As a network member, the company hopes to help reduce the US's reliance on overseas imports by providing domestic API capability
US start-up Phlow has been approved to join the Biomedical Advanced Research and Development Authority's (BARDA) CDMO network to provide domestic API manufacturing capability for essential medicines and medical countermeasures.
As part of the US government's BARDA network, Phlow will play its part in providing a domestically integrated, systematic approach to develop the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.
Network members are highly vetted manufacturers that are prequalified and ready to immediately deliver key medicines for the benefit of all Americans, while at the same time reducing the nation’s reliance on imports from foreign nations.
Currently, the CDMO is working with BARDA to put a US-based essential medicines supply chain solution into operation by developing APIs.
To improve the development and manufacturing of APIs and finished pharmaceutical products, Phlow is employing state-of-the-art green chemistry, continuous flow technology, and other advanced manufacturing processes.
Eric Edwards, president, co-founder, and CEO of Phlow said they, together with the US government, will ensure "preparedness for future national health crises".
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.